Nagoya University Bacterial Constipation Research: Gut Bacteria Duo Causes Chronic Constipation

Breakthrough in Gut Health: Nagoya University's Discovery of Bacterial Constipation

Researchers at Nagoya University have unveiled a groundbreaking study identifying a novel mechanism behind chronic constipation, termed 'bacterial constipation.' This condition arises when two specific gut bacteria collaborate to erode the protective mucus layer in the colon, leading to dry, hard stool that resists standard treatments. Published in the journal Gut Microbes, the research challenges long-held assumptions about constipation being primarily due to sluggish gut motility and opens new avenues for microbiome-targeted therapies.

Chronic idiopathic constipation (CIC), defined as persistent difficulty in passing stool without an identifiable cause, affects millions worldwide. In Japan, prevalence rates vary from 2% to 28% depending on diagnostic criteria, with higher incidences among women and the elderly. This Nagoya University-led investigation shifts focus from nerves and muscles to the colonic mucin—a gel-like substance that lubricates the intestines and hydrates feces—highlighting how microbial dysbiosis can trigger symptoms.

The Research Team and Publication Details

Led by Tomonari Hamaguchi, a lecturer in Nagoya University's Academic Research & Industry-Academia-Government Collaboration Office, the multidisciplinary team includes experts like Hiroshi Nishiwaki from the Graduate School of Medicine and Kinji Ohno. Their paper, titled 'Bacterial constipation: Mucin-degrading intestinal commensal bacteria cause constipation,' details rigorous experiments that pinpoint the microbial culprits.Access the full study here

Nagoya University, a leading Japanese institution renowned for its contributions to medical and biological sciences, continues to excel in gut microbiome research. This publication underscores the university's commitment to translational research, bridging basic science with clinical applications. For aspiring researchers, opportunities in such innovative labs abound—consider exploring research jobs or postdoc positions in higher education.

Identifying the Gut Bacteria Duo

The two bacteria at the heart of this discovery are Akkermansia muciniphila (A. muciniphila), a mucin-degrading anaerobe typically beneficial in moderation, and Bacteroides thetaiotaomicron (B. thetaiotaomicron), a common commensal that ferments complex carbohydrates. While both are normal residents of the human gut microbiome—the trillions of microorganisms influencing digestion, immunity, and metabolism—their synergistic overactivity depletes essential mucin.

In healthy guts, colonic mucin, produced by goblet cells in the intestinal epithelium, forms a double-layered barrier: an inner firm layer adhering to epithelial cells and an outer loose layer hosting commensals. Sulfate groups on mucin glycoproteins act as a shield against excessive degradation. When imbalanced, these bacteria disrupt this homeostasis.

Step-by-Step Mechanism of Mucin Degradation

The process unfolds sequentially, as elucidated by the Nagoya team:

• Sulfate Removal: B. thetaiotaomicron deploys sulfatase enzymes to strip protective sulfate groups from mucin, exposing vulnerable glycan chains.
• Mucin Consumption: A. muciniphila then attaches to the desulfated mucin, secreting glycosidases and other hydrolases to break it down and assimilate the sugars.
• Mucin Depletion: Accelerated degradation thins the mucus layer, reducing water retention in stool and causing it to harden.
• Constipation Onset: Dry feces adhere to the colon walls, impeding transit despite normal motility.

This microbiome-driven pathology explains why prokinetic agents and osmotic laxatives often fail in CIC patients.

Experimental Validation in Germ-Free Mice

To confirm causality, researchers colonized germ-free mice—animals lacking intestinal microbes—with the bacteria duo. These mice rapidly developed constipation symptoms, evidenced by reduced fecal output and mucin staining deficits. Crucially, genetically engineering B. thetaiotaomicron to lack functional sulfatase prevented degradation; co-colonized mice maintained intact mucin and normal defecation.

"We put these modified bacteria into germ-free mice together with A. muciniphila, and surprisingly the mice did not develop constipation; the mucin stayed protected and intact," Hamaguchi noted. This proof-of-concept paves the way for enzyme inhibitors as therapeutics.

Connection to Parkinson's Disease

Intriguingly, the study links bacterial constipation to Parkinson's disease (PD), a neurodegenerative disorder affecting over 1% of Japan's elderly. PD patients exhibit elevated A. muciniphila and B. thetaiotaomicron decades before motor symptoms, with constipation afflicting up to 80% early on. Traditionally ascribed to autonomic neuropathy, these findings implicate gut dysbiosis in prodromal PD, potentially via inflammatory metabolites breaching the mucus barrier and influencing the brain-gut axis.Nagoya University press release

Prior work by Nishiwaki's team on PD microbiomes reinforces this, showing consistent dysbiosis patterns.

Chronic Constipation Landscape in Japan

Japan faces a rising constipation burden amid aging demographics—over 29% of the population is 65+. Surveys report 28% self-recognized constipation, with CIC comprising 6-10% per Rome III criteria. Women report twice the rates, linked to hormonal shifts and lower fiber intake. Economic costs exceed ¥100 billion annually in treatments and productivity losses. This research spotlights the need for microbiome profiling in clinical practice.

Therapeutic Horizons and Sulfatase Blockers

Current therapies—bulk-forming laxatives (e.g., psyllium), stimulants (senna), or secretagogues (linaclotide)—target motility or secretion but overlook mucin loss. Hamaguchi's team proposes sulfatase inhibitors, small molecules blocking B. thetaiotaomicron's desulfation. Preclinical success suggests human trials, potentially revolutionizing care for 10-15 million Japanese CIC sufferers.

• Probiotics modulating A. muciniphila abundance.
• Dietary interventions boosting mucin production (e.g., prebiotics like inulin).
• Fecal microbiota transplantation (FMT) to restore balance.

For PD, early microbiome modulation could delay progression. Researchers eyeing clinical translation should check academic career advice.

Nagoya University's Microbiome Excellence

Nagoya University, founded in 1871, ranks among Japan's top research powerhouses, with strengths in medicine and biosciences. The Graduate School of Medicine hosts advanced facilities for metagenomics and gnotobiotic models. This study exemplifies collaborative efforts across divisions, fostering industry partnerships for drug development. Aspiring faculty can explore professor jobs or Japan higher ed opportunities.

Implications for Global Higher Education Research

This discovery elevates Japan's role in microbiome science, aligning with national initiatives like the Moonshot Research Program. It highlights interdisciplinary training needs—microbiology, genetics, neurology—in higher ed curricula. Universities worldwide can emulate Nagoya's model, integrating AI-driven metagenomics. For professionals, faculty positions in gut health research are booming.

Photo by Fotos on Unsplash

Future Directions and Actionable Insights

Upcoming studies may validate findings in human cohorts, test inhibitors in phase I trials, and explore dietary modulators. Patients can proactively support gut health via fiber-rich Japanese staples like natto or konjac, alongside hydration. Researchers, leverage this for grants; rate professors via Rate My Professor. Stay informed on university jobs and career advice in this dynamic field.